Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ebselen - Sound Pharmaceuticals

Next Previous
X
Search
Drug Profile

Ebselen - Sound Pharmaceuticals

Alternative Names: DR-3305; Ebselene; Ebseleno; Ebselenum; Harmokisane; PZ-51; SPI-1005; SPI-3005

Latest Information Update: 02 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nattermann
  • Developer Daiichi Sankyo Company; Medical University of South Carolina; Nattermann; Sound Pharmaceuticals; University of Oxford
  • Class Anti-ischaemics; Antiasthmatics; Antibacterials; Antiulcers; Antivirals; Azoles; Benzene derivatives; Ketones; Mood stabilisers; Neuroprotectants; Nonsteroidal anti-inflammatories; Organoselenium compounds; Small molecules; Vascular disorder therapies; Vestibular disorder therapies
  • Mechanism of Action Antioxidants; Cyclo-oxygenase 2 inhibitors; Glutathione peroxidase stimulants; Leukotriene B4 receptor antagonists; Prostaglandin receptor antagonists; Viral papain like protease inhibitors; Viral protein inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Meniere's disease
  • Phase II Bipolar disorders; COVID 2019 infections; Hearing loss; Noise-induced hearing loss; Sensorineural hearing loss; Tinnitus
  • Phase I Depressive disorders
  • Discontinued Asthma; Atherosclerosis; Cerebral infarction; Myocardial ischaemia; Peptic ulcer; Rheumatic disorders

Most Recent Events

  • 25 Jul 2024 Sound Pharmaceuticals completes phase III STOPMD-3 trial for Meniere's-disease in USA (PO) (NCT04677972)
  • 20 May 2024 US FDA approves IND application for Ebselen treatment in Sensorineural hearing loss and cochlear implantation
  • 01 Apr 2024 Sound Pharmaceuticals in collaboration with Med-El Corporation plans a phase II trial for Sensorineural hearing loss in July 2024 (PO) (NCT06340633)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top